Kong Yiu Cheung Buys 500,000 Shares of NewGenIvf Group (NASDAQ:NIVF) Stock

NewGenIvf Group Limited (NASDAQ:NIVF) Director Kong Yiu Cheung purchased 500,000 shares of the company’s stock in a transaction on Tuesday, June 2nd. The shares were purchased at an average cost of $1.33 per share, for a total transaction of $665,000.00. Following the completion of the transaction, the director directly owned 722,223 shares of the company’s stock, valued at approximately $960,556.59. This represents a 225.00% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.

Kong Yiu Cheung also recently made the following trade(s):

• On Monday, July 27th, Kong Yiu Cheung purchased 2,500,000 shares of NewGenIvf Group stock. The shares were acquired at an average cost of $1.00 per share, for a total transaction of $2,500,000.00.
• On Thursday, June 18th, Kong Yiu Cheung purchased 500,000 shares of NewGenIvf Group stock. The stock was acquired at an average price of $1.33 per share, for a total transaction of $665,000.00.

NewGenIvf Group Price Performance

NewGenIvf Group stock opened at $1.33 on Wednesday. The company has a debt-to-equity ratio of 0.16, a current ratio of 3.12 and a quick ratio of 2.98. The company’s 50-day moving average price is $2.96 and its two-hundred day moving average price is $11.34. NewGenIvf Group Limited has a twelve month low of $1.15 and a twelve month high of $1,539.00.

Analysts Set New Price Targets

Several research analysts have recently issued reports on the company. Weiss Ratings reaffirmed a “sell (d)” rating on shares of NewGenIvf Group in a research note on Friday, July 24th. Wall Street Zen upgraded shares of NewGenIvf Group to a “hold” rating in a report on Saturday, July 4th. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the stock has an average rating of “Sell”.

About NewGenIvf Group

NewGenIVF Group Inc, trading on NASDAQ under the symbol NIVF, is an integrated provider of reproductive medicine services in the People’s Republic of China. The company operates a network of fertility clinics across major Chinese cities, delivering comprehensive infertility diagnosis and treatment to patients and couples. Its facilities are equipped with modern laboratories and surgical suites designed for assisted reproductive procedures.

NewGenIVF’s service offerings encompass a wide range of assisted reproductive technologies (ART), including in vitro fertilization (IVF), intracytoplasmic sperm injection (ICSI), preimplantation genetic testing (PGT), and fertility preservation through ovarian tissue and gamete cryopreservation.